School of Medicine
Showing 1-10 of 48 Results
-
Norman J. Lacayo, MD
Associate Professor of Pediatrics (Hematology and Oncology)
Current Research and Scholarly InterestsPediatric Hematology/Oncology, Phase I drug studies for refractory and relapsed leukemia; genomic studies, biologic risk-stratification and treatment of acute myeloid leukemia; prediction or induction response and risk of relapse using phosphoproteomics in childhood AML; novel MRD techniques in childhood ALL.
-
Uri Ladabaum
Professor of Medicine (Gastroenterology and Hepatology)
Current Research and Scholarly InterestsGastrointestinal cancer prevention and risk management. Risk stratification. Cost-effectiveness analysis. Health services research.
-
Sheila Lahijani, MD, FACLP
Clinical Professor, Psychiatry and Behavioral Sciences - Medical Psychiatry
BioDr. Lahijani is a Clinical Professor of Medical Psychiatry at Stanford University School of Medicine and a nationally recognized leader in psycho-oncology. With extensive training and expertise in internal medicine, psychiatry, and consultation-liaison psychiatry, she has made significant contributions to the integration of psychiatric care within oncological settings.
Since her appointment at Stanford in 2015, Dr. Lahijani has served as the lead psychiatric oncologist at the Stanford Cancer Center, where she provides medical psychiatric consultation services and collaborates with interdisciplinary teams to enhance patient outcomes. In her capacity as Medical Director of the Stanford Cancer Center Psychosocial Oncology Program, a position she has held since 2019, she is responsible for the strategic development and implementation of comprehensive psychiatric services tailored to the unique needs of patients with cancer.
Additionally, Dr. Lahijani serves as the Section Chief of Psycho-Oncology in the Division of Medical Psychiatry where she oversees psych-onc faculty development and leads the training of medical psychiatry fellows in psycho-oncology. She also supervises advanced practice providers while also working as an attending psychiatric oncologist to provide care for patients with complex medical and psychiatric comorbidities across all hematology and oncology units.
Dr. Lahijani's academic credentials include her graduation from Brown Medical School, followed by the completion of a combined residency in Internal Medicine and Psychiatry at Rush University Medical Center. After completing residency, she practiced internal medicine and psychiatry with a focus on triple diagnosis (HIV, addiction medicine, mental health). She then further advanced through a Psychosomatic Medicine Fellowship at Northwestern University's Feinberg School of Medicine, during which time she received specialized training in psychiatric oncology at the Lurie Comprehensive Cancer Center and Memorial Sloan Kettering Cancer Center.
Her clinical expertise encompasses psychopharmacology and a range of treatment modalities, including Meaning Centered Psychotherapy and Dignity Therapy. Dr. Lahijani is deeply committed to fostering relationship-centered skills and promoting provider wellness. As a faculty member of Advancing Communication Excellence at Stanford, she has led workshops designed to enhance communication competencies among faculty and staff.
Dr. Lahijani's scholarly pursuits are at the intersection of medicine and psychiatry, with a particular emphasis on the neuropsychiatric sequelae of cancer treatment, innovations in care, and medical education. She is dedicated to the education and mentorship of trainees in Psychiatry, Internal Medicine, Hematology/Oncology, and Neurology. Through her commitment to academic excellence, Dr. Lahijani plays a pivotal role in preparing the next generation of healthcare providers to adeptly navigate the intricate and multifaceted needs of patients and their caregivers, thereby promoting a comprehensive approach to patient care. -
Marvin Langston
Assistant Professor of Epidemiology and Population Health and, by courtesy, of Urology
BioDr. Marvin Langston is an Assistant Professor of Epidemiology and Population Health. He is a member of the Stanford Cancer Institute and Urologic Cancer Epidemiology Lab. He is an epidemiologist by training who focuses on the fields of benign prostate and pelvic conditions and urological cancers including prostate and kidney cancers.
Prior to Stanford, he served as a Research Scientist in the Division of Research at Kaiser Permanente Northern California. Dr. Langston received his PhD in Epidemiology from the University of Arizona’s College of Public Health followed by postdoctoral training in Cancer Prevention and Control at Washington University in Saint Louis School of Medicine.
His program of research intends to characterize and measure infectious agents, environmental toxicants, and lifestyle factors; to evaluate the role of these factors in urological cancer etiology and outcomes; and to identify populations at high risk of exposure to these factors. So far he has focused this research to address the following questions: 1) What role do sexually transmitted infections and other systemic infections have in prostate damage and ensuing prostate cancer risk? 2) How can we appropriately model and define early life risk factors for urological cancers? 3) Can we harmonize molecular and clinical aspects of urological condition diagnoses to produce well characterized outcomes for biomarker discovery and etiological investigation? He has primarily addressed these questions using a variety of molecular and clinical epidemiology approaches while developing expertise in the cross-cutting theme of cancer health disparities with particular interests in the cancer care experiences of sexual and gender minorities and racial/ethnic minorities.
Dr. Langston has been studying the impact of exogenous factors on prostate specific antigen (PSA) concentration in young men as a marker of prostate damage and inflammation for over a decade. As early life PSA has been found predictive of future prostate cancer mortality, he has now setout to optimize risk-stratified screening for prostate cancer. This promising approach uses men’s baseline PSA values to inform their risk of future aggressive and/or fatal prostate cancer and determine their frequency of further screening. Under this approach, men with high baseline age-specific total PSA levels receive more frequent screening and men with lower levels receive less frequent screening. Dr. Langston was awarded an R01 from NCI to evaluate this approach using historically collected biospecimen. His funded research trajectory to this point also includes four training awards (2-NCI and 2-NIDDK) and several internal grants. Dr. Langston was selected in the inaugural class of the White House Cancer Moonshot Scholars for his work. -
Philip W. Lavori
Professor of Biomedical Data Science, Emeritus
Current Research and Scholarly InterestsBiostatistics, clinical trials, longitudinal studies, casual inference from observational studies, genetic tissue banking, informed consent. Trial designs for dynamic (adaptive) treatment regimes, psychiatric research, cancer.
-
Quynh-Thu Le, MD, FACR, FASTRO, FARS
Katharine Dexter McCormick and Stanley McCormick Memorial Professor and Professor, by courtesy, of Otolaryngology - Head & Neck Surgery (OHNS)
Current Research and Scholarly InterestsMy laboratory focuses on identifying pathways and biomarkers of treatment resistance in head and neck cancer using clinical samples. We explore approaches to modulate these pathways through preclinical models (cell lines, organoids, tumor bearing mice) in order to develop precise strategies against these resistant mechanisms. At the same time, we are also studying pathways involved in treatment-related toxicity and develop strategies to prevent or overcome these toxicities.
-
Byrne Lee, MD FACS
Clinical Professor, Surgery - General Surgery
BioDr. Lee is a native of New York City. He attended the Sophie Davis School of Biomedical Education at the City College of New York and received his medical degree from New York Medical College. He completed general surgery residency training at Lenox Hill Hospital and fellowship training in surgical oncology at the City of Hope National Cancer Center. Dr. Lee led the Peritoneal Surface Malignancy Program at City of Hope prior to joining Stanford in 2019.
Dr. Lee is a surgical oncologist who specializes in the treatment of gastrointestinal malignancies. He has dedicated his clinical practice to the surgical management of metastatic disease, particularly to the liver and peritoneum. He has expertise in delivering regional cancer therapies such as heated intraperitoneal chemotherapy (HIPEC). Additionally, he performs surgery for cancers of the stomach, liver, pancreas, small intestine, colon, and soft tissue sarcoma. He utilizes minimally invasive and robotic surgical techniques when appropriate.
Dr. Lee leads the Regional Cancer Therapies program at Stanford. The program implements and develops novel treatment strategies for patients affected with peritoneal malignancies and oligometastatic disease to the liver. His research focus is on clinical outcomes of multidisciplinary management for gastric, hepatobiliary, and peritoneal surface malignancies. He is a member of a national consensus group performing collaborative research and developing clinical trials for HIPEC surgeries. -
Jennifer Lee
Professor of Medicine (Endocrinology) and, by courtesy, of Epidemiology and Population Health
Current Research and Scholarly InterestsI am a healthcare lead and physician scientist for innovation, R&D, and advanced analytics, and oversee these aspects at VA Palo Alto/VHA, within Stanford-VA relationship. The VA has the US's largest health care system and longest running EHR. I prioritize enabling multiple partners (industry, government, academia, foundations), to innovate/R&D in the VA health care system. We prioritize mentoring students from various Schools to become future leaders in R&D, innovation, and healthcare.
-
John Leppert
Professor of Urology and, by courtesy, of Nephrology
Current Research and Scholarly InterestsOur research aims to improve the global quality of care for patients with Urologic Cancer with a particular focus on kidney cancer. We are investigating novel proteomic platforms and assays to diagnose kidney cancer and predict response to therapy. We are evaluating the comparative effectiveness of various kidney cancer surgeries and their impact on chronic kidney disease and its downstream effects. We are applying epidemiology, bioinformatics, and health services methods to urologic conditions.
